This is the second in a series of vignettes illustrating methods for evaluating the fit and efficiency of three state oncology cost-effectiveness model structures, as described in an accompanying journal article (Muston 2024). The package is heavily dependent on flexsurv (Jackson 2016).

After fitting models, as described in
`vignette("example")`

, estimates of Restricted Mean Durations
(RMDs) in health states can be calculated after constraining for
background mortality from a given life table.

We denote functions of survival, hazard and cumulative hazard as \(S(t), h(t)\) and \(H(t)\). There are ‘unadjusted’ values for relevant endpoints (e.g. PFS) dependent on the model structure (PSM, STM-CF or STM-CR). We assume that there is a ‘general background mortality’, against which any extrapolations and derivations of RMD should be constrained, denoted with subscript ‘gen’. Consequently there are ‘adjusted’ values, denoted with superscript ‘adj’.

Our lifetable gives us decreasing \(l_x\) values at points between \(t=0, ..., t_{max}\), with \(l_{t_{max}}=0\). Let us define the background mortality survival function as follows.

\[ S_{gen}(t) = 1 - R \left(1 - \frac{l_{x_0 + t}}{l_{x_0}} \right) \]

where \(x_0\) is the mean age of the study population at baseline, \(R\) is a Standardized Mortality Ratio, and \(l_x\) is an appropriate lifetable.

We can also derive the average background mortality hazard for \(t\) in the range \([t_1, t_2)\).

\[ h_{gen}(t) = \frac{\log[S_{gen}(t_1)] - \log[S_{gen}(t_2)]}{t_2 - t_1} \]

There are a number of approaches applied in literature and HTA submissions, so it could mean several things!

Under this approach, the background mortality is assumed to limit the survival function as follows. There is no direct constraint to the hazard.

\[ S^{adj}(t) = \min \left[ S(t), S_{gen}(t) \right] \]

This is a simple approach, and has been used at least one NICE technology appraisal (National Institute for Health and Care Excellence 2022):

“Patient longevity is always the lesser of values generated from the disease-specific survival curve (after adjustment for treatment and functional status) and the survival curve for the general population according to age and sex.”

However, this approach does not ensure that the hazard is at least as great as the hazard of background mortality.

A more rigorous adjustment would be that the hazard of background mortality acts as a constraint to the unadjusted hazard (Sweeting et al. 2023).

\[ h^{adj}(t) = \max \left[ h(t), h_{gen}(t) \right] \] \[ \implies S^{adj}(t) = \exp \left[ - \int_0^t h^{adj}(u) du \right] \]

In either case, we must assume that the original dataset was NOT subject to background mortality. Although unlikely to be true, this is a common, pragmatic assumption in cost-effectiveness models as long as background mortality is relatively insignificant during trial follow-up.

The above approaches work by adjusting extrapolations made from models fitted to data assumed to be not subject to background mortality. If - as is likely - the population in the dataset were in fact subject to background mortality, then it would be better to model that dataset using excess hazard methods rather than to seek to make adjustments to extrapolations after the fact. Further discussion of survival extrapolation incorporating general population mortality is provided by Sweeting et al. (2023).

As discussed previously, state transition models with three states may be clock forward (‘STM-CF’) or ‘clock reset’ (STM-CR). Such structures involve modeling each transition directly, which may be performed by fitting survival distributions to the TTP, PPD and PPS endpoints.

In general, we wish to constrain the pre- and post-progression mortality (PPD and PPS) are at least as great as background mortality.

\[ h^{adj}_{PPD}(t) = \max \left[h_{gen}(t), h_{PPD}(t) \right] \\ h^{adj}_{PPS}(t) = \max \left[h_{gen}(t), h_{PPS}(t) \right] \\ \]

Formulas for the mean time in PF and OS are shown in the accompanying article in respect of hazard and survival functions for TTP, PPD and PPS endpoints, where PPS is a function of time from baseline in a Clock Forward (CF) and time from progression in a Clock Reset (CR) model. Adjusting for background mortality requires using the adjusted rather than unadjusted hazards for PPD and PPS in formulae.

This is straightforward enough for the PPD endpoint in the STM-CF and STM-CR structures, and for the PPS endpoint in the STM-CF structure. However matters are more complex for the PPS endpoint for the STM-CF since its hazard and survival are functions of two times (time from progression and time from baseline) rather than just one (time from baseline). This package does not provide integral solutions relying on continuous time for RMDs, and must instead rely on discretization.

Spreadsheet-based economic models almost always rely on discretizing time into timesteps rather than follow the integral formulas described above for continuous time. As long as timesteps are reasonably short, restricted mean duration results should remain reasonably accurate. Derided as a “kludge”, half-cycle corrections are nevertheless recommended (Naimark, Kabboul, and Krahn 2013). The package provides discretized calculations.

The RMD in the PF state and time alive are integrals over the time horizon, \(T\), of the survival functions of the endpoints PFS and OS. Endpoints PPD and PPS are not explicitly defined.

However as discussed in the accompanying manuscript, TTP - and therefore the PPD and PPS endpoints which directly follow once PFS and OS are defined - are often in practice implicitly defined in PSM economic model in order to calculate payoffs that depend on progression events. Two methods are possible:

Simple (default): the hazard of TTP relative to PFS is proportionate to the progression events observed over the follow-up period relative to the total number of observed PFS events.

Complex: the hazard of TTP is directly modeled by fitting survival distributions as with other endpoints.

The adjustment to RMD estimates can then proceed as with the STMs, with hazards and survival functions of TTP, PPD and PPS that reflect the PSM structure (in which PFS and OS endpoints are first estimated), a chosen model of progression (simple or complex), and then finally the adjustment to PPD and PPS for background mortality.

First we load the packages we need - all of which are suggested for
or imported to *psm3mkv*. If you haven’t installed
*psm3mkv* yet, please see the installation
instructions to install it with its dependencies. Of these, we will
making further use of Wickham et al.
(2023), Riffe (2015) and Müller and Wickham (2023).

In order to apply constraints to background mortality, we need some
background mortality data, in the form of a lifetable. We can take this
from the Human Mortality Database using the *HMDHFDplus* package
mentioned above (with thanks to Robert Hettle for the recommendation).
The lifetable will need to start from an assumed age at baseline.
Lifetables are constructed by time in years.

```
# HMD HFD package
library("HMDHFDplus")
# Assumed population age at baseline (time=0)
baseage <- 51.0
# Mortality data - England & Wales, Female, 2019
mort <- readHMDweb(
CNTRY = "GBRTENW",
item = "fltper_1x1",
username = "",
password = ""
) |>
filter(Year == 2019) |>
select(Age, lx, dx) |>
mutate(Timey = ceiling(Age - baseage)) |>
filter(Timey >= 0)
# The table needs to end with lx=0
mort <- add_row(mort, Age = 111, lx = 0, Timey = 60)
```

You will see that the above code cannot run without a login for the Human Mortality Database. Alternatively, we could just make up a mortality table.

```
mort <- tibble(
Timey = 0:30,
lx = 10000 * exp(-0.03 * Timey^1.1),
dx = lx - lead(lx),
qx = dx / lx
)
```

However we do it, once we have the mortality data, we can apply the SMR (\(R\)) and derive a lifetable from time zero as required.

```
# Assumed Standardized Mortality Ratio
SMR <- 2
# Recalculate the lifetable with the SMR applied
mort$adjlx <- mort$lx
for (i in 2:length(mort$lx)) {
mort$adjlx[i] <- mort$adjlx[i - 1] * (1 - SMR * mort$qx[i - 1])
}
# Ensure lx>=0
mort$adjlx[mort$adjlx < 0] <- 0
# Create and view lifetable
ltable <- tibble(lttime = mort$Timey, lx = mort$adjlx)
head(ltable)
#> # A tibble: 6 × 2
#> lttime lx
#> <int> <dbl>
#> 1 0 10000
#> 2 1 9409.
#> 3 2 8774.
#> 4 3 8151.
#> 5 4 7553.
#> 6 5 6985.
```

Next we get some patient-level data and fit the PSM and STMs. So far,
we are closely following `vignette("example")`

. Time is
assumed to be recorded in the patient-level data in weeks, with
approximately 52.18 weeks per year.

```
# Get some data
bosonc <- create_dummydata("flexbosms")
# We'll make the durations a lot longer
# so that they will be definitely constrained by the lifetable
bosonc <- bosonc |>
mutate(
pfs.durn = 20 * pfs.durn,
os.durn = 20 * os.durn,
ttp.durn = 20 * ttp.durn
)
# Fit parametric models to each endpoint
allfits <- fit_ends_mods_par(bosonc)
# Bring together preferred fits for each endpoint
params <- list(
ppd = find_bestfit(allfits$ppd, "aic")$fit,
ttp = find_bestfit(allfits$ttp, "aic")$fit,
pfs = find_bestfit(allfits$pfs, "aic")$fit,
os = find_bestfit(allfits$os, "aic")$fit,
pps_cf = find_bestfit(allfits$pps_cf, "aic")$fit,
pps_cr = find_bestfit(allfits$pps_cr, "aic")$fit
)
```

We are skipping over any internal or external validation for the purposes of this vignette, and jump instead straight to making the survival projections. We will assume a 10 year time horizon.

First we derive a projection using integral formulae, without lifetable constraints.

```
# Set time horizon
thoz <- 10
# Run the calculations
proj1 <- calc_allrmds(bosonc, dpam = params, Ty = thoz)
# Present the results
res1 <- proj1$results |> mutate(method = "int", lxadj = "no", psmmeth = "simple")
res1 |> mutate(
across(c(pf, pd, os), ~ num(.x, digits = 1))
)
#> # A tibble: 3 × 7
#> pf pd os model method lxadj psmmeth
#> <num:.1!> <num:.1!> <num:.1!> <chr> <chr> <chr> <chr>
#> 1 274.4 118.3 392.7 PSM int no simple
#> 2 270.2 119.7 389.9 STM-CF int no simple
#> 3 270.2 123.8 393.9 STM-CR int no simple
```

Next we derive a projection using a discretization approximation, still without any lifetable constraints.

```
# Run the calculation
proj2 <- calc_allrmds(bosonc, dpam = params, Ty = thoz, rmdmethod = "disc")
# Present the results
res2 <- proj2$results |>
mutate(method = "disc", lxadj = "no", psmmeth = "simple")
res2 |> mutate(
across(c(pf, pd, os), ~ num(.x, digits = 1))
)
#> # A tibble: 3 × 7
#> pf pd os model method lxadj psmmeth
#> <num:.1!> <num:.1!> <num:.1!> <chr> <chr> <chr> <chr>
#> 1 274.3 118.3 392.6 PSM disc no simple
#> 2 270.1 119.7 389.8 STM-CF disc no simple
#> 3 270.1 123.7 393.8 STM-CR disc no simple
```

Discretization has proven fairly accurate. The STM-CR estimate of mean time alive has reduced by just 0.1 weeks for example, from 393.9 to 393.8 weeks.

Finally, we use a discretization approximation and apply the lifetable constraints.

```
# Run the calculations
proj3 <- calc_allrmds(bosonc, dpam = params, Ty = thoz, rmdmethod = "disc", lifetable = ltable)
# Present the results
res3 <- proj3$results |>
mutate(method = "disc", lxadj = "yes", psmmeth = "simple")
res3 |> mutate(
across(c(pf, pd, os), ~ num(.x, digits = 1))
)
#> # A tibble: 3 × 7
#> pf pd os model method lxadj psmmeth
#> <num:.1!> <num:.1!> <num:.1!> <chr> <chr> <chr> <chr>
#> 1 235.4 105.5 340.9 PSM disc yes simple
#> 2 230.1 107.6 337.7 STM-CF disc yes simple
#> 3 230.1 111.6 341.6 STM-CR disc yes simple
# Proportion of time alive spent in PF
proppf3 <- res3$pf / res3$os
```

There is now some difference between the STM-CR compared to the STM-CF and PSM structures. All structures estimate fairly similar RMD estimates of being alive (range: 337.7 to 341.6 weeks). The estimate of mean time alive in the STM-CR structure has reduced by 52.3 weeks from 393.9 to 341.6 weeks.

The proportion of that time in the PF rather than PD state varies somewhat (PSM: 69%, STM-CF: 68.1%, STM-CR: 67.3%). Given that the hazard of mortality would typically be lower before rather than after progression, the pre-progression mortality is likely to be more affected by any mortality constraint that post-progression mortality. The STM-CR model of post-progression survival depends on time from progression and is therefore rather different from the STM-CF and PSM structures, which model mortality based on time from baseline.

We can check whether using a ‘complex’ type of PSM structure rather than the default ‘simple’ affects RMD estimates from the PSM structure.

```
# Run the calculations
proj4 <- calc_allrmds(bosonc, dpam = params, Ty = thoz, psmtype = "complex", rmdmethod = "disc", lifetable = ltable)
# Present the results
res4 <- proj4$results |>
mutate(method = "disc", lxadj = "yes", psmmeth = "complex")
res4 |> mutate(
across(c(pf, pd, os), ~ num(.x, digits = 1))
)
#> # A tibble: 3 × 7
#> pf pd os model method lxadj psmmeth
#> <num:.1!> <num:.1!> <num:.1!> <chr> <chr> <chr> <chr>
#> 1 231.0 103.7 334.7 PSM disc yes complex
#> 2 230.1 107.6 337.7 STM-CF disc yes complex
#> 3 230.1 111.6 341.6 STM-CR disc yes complex
# Proportion of time alive spent in PF
proppf4 <- res4$pf / res4$os
```

All structures estimate fairly similar RMD estimates of being alive (range: 334.7 to 341.6 weeks). The proportion of that time in the PF rather than PD state varied a little by model structure (PSM: 69%, STM-CF: 68.1%, STM-CR: 67.3%).

A summary of the STM-CF estimates of mean time in PF state and mean time alive is given in the table below.

Model | Mean time in PF (weeks) | Change (weeks) | Mean time alive (weeks) | Change (weeks) |
---|---|---|---|---|

No lifetable constraint, integral methods | 270.2 | - | 389.9 | - |

No lifetable constraint, discretized calculation | 270.1 | -0.1 | 389.8 | -0.1 |

With lifetable constraint, discretized calculation | 230.1 | -40.1 | 337.7 | -52.2 |

In this fictional case, the application of a lifetable constraint had fairly sizeable effects on the results - although this was by design of this demonstration.

A summary of the STM-CR estimates of mean time in PF state and mean time alive is given in the table below.

Model | Mean time in PF (weeks) | Change (weeks) | Mean time alive (weeks) | Change (weeks) |
---|---|---|---|---|

No lifetable constraint, integral methods | 270.2 | - | 393.9 | - |

No lifetable constraint, discretized calculation | 270.1 | -0.1 | 393.8 | -0.1 |

With lifetable constraint, discretized calculation | 230.1 | -40.1 | 341.6 | -52.3 |

The application of a lifetable constraint had similar and fairly sizeable effects on the results here also.

A summary of the PSM estimates of mean time in PF state and mean time alive is given in the table below.

Model | Mean time in PF (weeks) | Change (weeks) | Mean time alive (weeks) | Change (weeks) |
---|---|---|---|---|

No lifetable constraint, integral methods, simple PSM | 274.4 | - | 392.7 | - |

No lifetable constraint, discretized calculation, simple PSM | 274.3 | -0.1 | 392.6 | -0.1 |

With lifetable constraint, discretized calculation, simple PSM | 235.4 | -39 | 340.9 | -51.8 |

With lifetable constraint, discretized calculation, complex PSM | 231 | -43.4 | 334.7 | -58.1 |

The change in the RMDs for the ‘complex’ PSM structure compared to the ‘simple’ PSM structure were -4.3, -1.9 and -6.2 weeks respectively for time in PF state, PD state and time alive.

Not applied here, the package also allows application of discounting
through the `discrate`

optional call to
`calc_allrnds()`

. This work could also be easily extended
through calculating RMDs or Life Years that are Quality Adjusted
(QALYs).

Jackson, Christopher. 2016. “flexsurv:
A Platform for Parametric Survival Modeling in R.”
*Journal of Statistical Software* 70 (8): 1–33.

Müller, Kirill, and Hadley Wickham. 2023. *tibble: Simple Data Frames*. https://CRAN.R-project.org/package=tibble.

Muston, Dominic. 2024. “Informing Structural Assumptions for Three
State Oncology Cost-Effectiveness Models Through Model Efficiency and
Fit.” *Applied Health Economics and Health Policy*. https://doi.org/10.1007/s40258-024-00884-2.

Naimark, David MJ, Nader N Kabboul, and Murray D Krahn. 2013. “The
Half-Cycle Correction Revisited: Redemption of a Kludge.”
*Medical Decision Making* 33 (7): 961–70.

National Institute for Health and Care Excellence. 2022.
“Avalglucosidase Alfa for Treating Pompe
Disease.” Technology appraisal guidance TA821. London, UK:
National Institute for Health; Care Excellence. https://www.nice.org.uk/guidance/ta821/documents/committee-papers.

Riffe, Tim. 2015. “Reading Human Fertility Database and Human
Mortality Database Data into R.” TR-2015-004. MPIDR.
https://doi.org/10.4054/MPIDR-TR-2015-004.

Sweeting, Michael J, Mark J Rutherford, Dan Jackson, Sangyu Lee,
Nicholas R Latimer, Robert Hettle, and Paul C Lambert. 2023.
“Survival Extrapolation Incorporating General Population Mortality
Using Excess Hazard and Cure Models: A Tutorial.” *Medical
Decision Making* 43 (6): 737–48.

Wickham, Hadley, Romain François, Lionel Henry, Kirill Müller, and Davis
Vaughan. 2023. *dplyr: A Grammar of Data
Manipulation*. https://CRAN.R-project.org/package=dplyr.